Actively Recruiting
Neurocognitive Assessment Platform 4 Alzheimer
Led by IRCCS San Raffaele · Updated on 2026-01-22
100
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers. The Neurocognitive Assessment Platform 4 Alzheimer (NAP4A) study aims to create a digital platform for the early detection of amnestic mild cognitive impairment (MCIa), considered an intermediate stage between normal aging and dementia. The platform uses non-invasive biometric tools, including EEG, blood flow sensors, and eye-tracking devices, to collect neurophysiological and behavioral data. The study will involve 100 participants aged 55 to 80, divided into two groups: one with individuals diagnosed with MCIa and a control group of healthy participants. Over 12 months, regular assessments will be conducted to identify markers that predict the progression from MCIa to AD. The goal is to develop advanced diagnostic tools that support early and targeted interventions.
CONDITIONS
Official Title
Neurocognitive Assessment Platform 4 Alzheimer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Aged between 55 and 80 years
- No or minimal impact on daily living or instrumental activities
- For healthy controls: Mini Mental State Examination score of 28 or higher
- For healthy controls: No abnormal cognitive deficits for age, sex, and education level
- For aMCI group: Cognitive difficulties reported by self, family, or physician
- For aMCI group: Mini Mental State Examination score near average for age and education
- For aMCI group: Specific memory-related or multi-domain cognitive deficits atypical for age
You will not qualify if you...
- Declined informed consent
- Significant sensory deficits such as hearing loss or hypovisus
- Current or past psychiatric illness
- Current or past degenerative central nervous system diseases
- History of systemic diseases
- History of cerebrovascular events
- History of alcohol or psychotropic substance use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS San Raffele
Milan, Italy, Italy, 20132
Actively Recruiting
Research Team
E
Elisa Canu, PhD
CONTACT
V
Virginia Sanchini, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here